NASDAQ:IRWD Ironwood Pharmaceuticals Q2 2026 Earnings Report $4.31 -0.11 (-2.49%) Closing price 04:00 PM EasternExtended Trading$4.37 +0.06 (+1.37%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Ironwood Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS $0.32Beat/MissN/AOne Year Ago EPSN/AIronwood Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$114.84 millionBeat/MissN/AYoY Revenue GrowthN/AIronwood Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Ironwood Pharmaceuticals Earnings HeadlinesIronwood Pharmaceuticals (NASDAQ:IRWD) Trading Up 8.7% - Here's WhyAugust 2 at 4:32 AM | americanbankingnews.comBrokerages Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) PT at $6.23August 2 at 3:58 AM | americanbankingnews.comTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move.August 4 at 1:00 AM | Porter & Company (Ad)Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update CallJuly 30, 2026 | businesswire.comIronwood Pharmaceuticals: One Trial Stands Between Bargain And BustJuly 30, 2026 | seekingalpha.comTop profitable small caps trading at bargain P/E multiples during Q2 earningsJuly 27, 2026 | msn.comSee More Ironwood Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ironwood Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ironwood Pharmaceuticals and other key companies, straight to your email. Email Address About Ironwood PharmaceuticalsIronwood Pharmaceuticals (NASDAQ:IRWD) is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S. markets under the brand name CONSTELLA. In addition to its marketed therapy, Ironwood maintains a diversified pipeline of clinical and preclinical programs targeting GI motility, inflammation and neurological conditions. Lead pipeline candidates include novel small molecules designed to modulate gut motility and secretions, as well as agents aimed at central nervous system targets to address pain and neurodegenerative disorders. The company leverages in-house research capabilities alongside external partnerships to advance its portfolio. Founded in 1998 as Microbia Biosciences, the business rebranded as Ironwood Pharmaceuticals in 2010 concurrent with its initial public offering. Headquartered in Cambridge, Massachusetts, Ironwood conducts research and development activities in the U.S. and collaborates with global pharmaceutical partners to extend its reach into European, Canadian and other international markets. Ironwood is led by President and Chief Executive Officer Peter Hecht, who brings extensive experience in both commercial operations and strategic development within the biopharmaceutical industry. Under his leadership, the company continues to pursue innovative therapies aimed at addressing unmet needs in GI health and related therapeutic areas.View Ironwood Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise QuarterThe AI Chip Stock Making a Quiet Move Toward DominanceApple’s AI Strategy Looks Different—Will It Pay Off?Reddit’s U.S. User Decline Raises a Bigger Question After Its Earnings BeatWhy Walmart and Amazon Could Be the Market’s Most Complementary Mega-CapsMarriott’s Earnings Drop May Be Missing the Bigger Fee Growth StoryDodging Deutsche Telekom: T-Mobile's Strategic Win Upcoming Earnings DoorDash (8/5/2026)Walt Disney (8/5/2026)MercadoLibre (8/5/2026)Occidental Petroleum (8/5/2026)Phillips 66 (8/5/2026)Allstate (8/5/2026)Brookfield Asset Management (8/5/2026)MetLife (8/5/2026)Manulife Financial (8/5/2026)Block (8/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
